title: Value of PET/CT in the management of liver metastases, part 1.
abstract: OBJECTIVE
  Metastasis is the most common (95%) of liver lesions. Early diagnosis and staging are the keys to treatment planning and prognosis. There is a consistent benefit to the use of PET/CT for detecting hepatic, local, and distant metastases from a variety of primary malignancies, which can contribute to staging and ultimately helps to establish the best course of treatment and to determine prognosis.
  
  
  CONCLUSIONS
  For colorectal cancer, FDG PET and FDG PET/CT are particularly effective for identification of additional hepatic and extrahepatic metastases, frequently upstaging the tumor stage and affecting management. In addition, PET/CT is very useful in local ablative and systemic therapy assessment and surveillance for liver metastases.
authors.affiliation: Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Ari
authors.initials: A
authors.lastname: Sacks
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Peller
authors.forename: Devaki S
authors.initials: DS
authors.lastname: Surasi
authors.forename: Luke
authors.initials: L
authors.lastname: Chatburn
authors.forename: Gustavo
authors.initials: G
authors.lastname: Mercier
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary* / Q000628:therapy; D009367:Neoplasm Staging; D011859:Radiography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18